On the other hand, those companies content to explore sub-blockbuster opportunities in genetically defined markets have two economic incentives to do so. The first is that it could be much cheaper. Statistical considerations alone dictate that the clinical trials-the largest cost component in drug development-of a highly efficacious medicine will be much lower than those of a marginally efficacious one. If one can exclude poor responders by genetic diagnosis, then fewer patients will need to be trialed to demonstrate a statistically significant improvement over existing therapies. The economics of this are exemplified by Genentech's Herceptin, a monoclonal antibody drug used in the treatment of metastatic breast cancer patients overexpressing the HER2 marker. In 2002, the drug generated sales of $385 million which, assuming a 40% operating margin, is roughly enough to recuperate the estimated $150 million developmental cost from a single year's sales. Several other prominent biotechnology companies have adopted the same development template. Vertex Pharmaceuticals is collaborating with deCODE Genetics to incorporate genetic profiling into its clinical trials of VX-148, an experimental small molecule for treating psoriasis. And Biogen is teaming up with SurroMed to study the response of multiple sclerosis patients to its Avonex therapy.
The other economic incentive for biotechnology companies to get into genetically defined markets is the prospect of product protection under orphan drug rules. Both the FDA and the European Medicine Evaluation Agency have indicated that genetic markers could in theory be used to define a population of less than 200,000 patients and allow designation as orphan indications. If genetics could be used to define new orphan subtypes of a molecularly heterogeneous disease (breaking hypertension down into 15 different molecularly defined subtypes, for instance), new markets could open.
The bottom line is that personal medicine does not have to wait for regulatory agencies to impose safety or efficacy constraints. The day of genetic tests for avoiding adverse reactions will come, but only when our molecular understanding of drug metabolism and side effects is much more complete. In the meantime, economic incentives can already drive the emergence of genetically defined efficacy. While pharma companies will not proactively segment their existing markets, they will find them being segmented nevertheless-by a biotechnology product that provides better efficacy to this genetically defined group, by another product that works better for another segment, and so on. Not exactly death by a thousand cuts, but death by a thousand SNPs, perhaps. Furthermore, the diagnostic assessment need not be a barrier to a drug's success. It is just as likely to be perceived as an eligibility criterion reinforcing the premium value of the associated drug, a biological platinum card that opens up a world of medical privilege.
Five years ago, personalized medicine was hailed as the next 'revolution' in drug development. The revolution has been a long time coming. But if it is based on economic realities, not regulatory caprice, moleculardefined medicine will indeed prove sustainable and irresistible.
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